A Phase 1b/2, Open-label, Dose-finding Study To Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Either Crizotinib Or Pf-06463922 In Patients With Advanced Or Metastatic Non-small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Avelumab (Primary) ; Crizotinib; Lorlatinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Javelin Lung 101
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Planned End Date changed from 13 Jan 2018 to 14 Jan 2018.
- 06 Jun 2017 Planned primary completion date changed from 13 Jan 2018 to 14 Jan 2018.